Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.57 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7289138 | 1.00 | KDM4E (0.57) | KDM4EKMT2ASIGMAR1LTA4HDRD2 | |
| SCHEMBL27350521 | 0.91 | SLC6A3 (0.61) | SIGMAR1LTA4HDRD2DRD3 | |
| SCHEMBL21197752 | 0.91 | SLC6A3 (0.61) | SIGMAR1LTA4HDRD2DRD3 | |
| SCHEMBL25285380 | 0.91 | SLC6A3 (0.61) | SIGMAR1LTA4HDRD2DRD3 | |
| SCHEMBL20683762 | 0.85 | KDM4E (0.46) | KDM4EKMT2ALTA4H | |
| SCHEMBL31039760 | 0.83 | LTA4H (0.55) | KDM4ELTA4H | |
| SCHEMBL20683798 | 0.82 | HRH3 (0.55) | SIGMAR1LTA4HDRD2 | |
| SCHEMBL20683799 | 0.82 | HRH3 (0.55) | SIGMAR1LTA4HDRD2 | |
| SCHEMBL20683715 | 0.82 | HRH3 (0.55) | SIGMAR1LTA4HDRD2 | |
| SCHEMBL19850993 | 0.82 | L3MBTL1 (0.62) | KDM4EKMT2ASIGMAR1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1981877-B1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2012-04-18 | — | — | EP | disclosed |
| US-7750155-B2 | Pyrazinyl hydroxyacrylamide compounds having an inhibitory effect on the activity of histone deacetylase | ASTELLAS PHARMA INC. (JP) | 2010-07-06 | — | — | US | disclosed |
| US-20090054465-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLA PHARMA INC. (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1981877-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | Astellas Pharma Inc. (JP) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007091703-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054465-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | HDAC1, HDAC6, HDAC5 | KDM4E 450/4885KMT2A 67/4885SIGMAR1 2656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.